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Abstract:  
Receptor Interacting Serine/Threonine Kinase 1 (RIPK1) is a master regulator of 
signaling pathways leading to inflammation and cell death and is of medical interest as a 
drug target.  Here, we report four patients from three unrelated families with complete 
RIPK1 deficiency caused by rare homozygous mutations. The patients suffered from 
recurrent infections, early-onset inflammatory bowel disease and progressive 
polyarthritis. They had immunodeficiency with lymphopenia and altered production of 
various cytokines revealed by whole-blood assays. In vitro, RIPK1-deficient cells showed 
impaired MAPK activation and cytokine secretion and were prone to necroptosis.  
Hematopoietic stem cell transplantation reversed cytokine production defects and 
resolved clinical symptoms in one patient. Thus, RIPK1 plays a critical role in the human 
immune system. 
 
 
Main Text:  
Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders characterized by 
increased susceptibility to infections. In many cases PIDs are monogenic disorders that follow 
Mendelian inheritance and mutations in more than 300 genes have been shown to cause PIDs 
(1). However, in many PID patients causative mutations remain unknown. Identification of 
such mutations not only facilitates diagnosis of PIDs, but also can provide the fundamental 
knowledge about the roles of the affected proteins in the human immune system. 
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Here, we used exome sequencing to identify causative mutations in a heterogeneous 
cohort of PID patients with unknown genetic etiology (2). We excluded known polymorphisms 
(2) and studied rare variants. We noticed that four patients (P1 – P4) from three unrelated 
consanguineous families (Fig. 1A) had homozygous loss-of-function mutations in the same 
gene, RIPK1 (ENST00000380409). In patients P1 and P2 from family A, the mutation was a 4-
nucleotide frameshift deletion in RIPK1 exon 6 that led to a premature stop codon (Fig. 1B). In 
patient P3 from family B, we found a 21-nucleotide deletion that removed one nucleotide in 
RIPK1 exon 4 and 20 nucleotides in the following intron (Fig. 1B). This deletion activated an 
alternative splice site in intron 4, so that the RIPK1 transcript lacked the last nucleotide of exon 
4 and had an insertion of 48 nucleotides from the following intron (fig. S1). Patient P4 from 
family C had a homozygous 2,064-nucleotide deletion that completely removed RIPK1 exon 4 
(Fig. 1B and fig. S2). Parents of all patients were heterozygous carriers of these RIPK1 
mutations (Fig. 1A and fig. S3). Given that homozygous loss-of-function mutations in the 
RIPK1 gene had never been reported in humans (e.g., absent from more than 120,000 subjects 
in the gnomAD database (3)), such mutations in our patients are likely to be pathogenic. The 
RIPK1 gene encodes a 671 amino-acid serine/threonine kinase (Fig. 1C). All three mutations 
mapped to the N-terminal kinase domain and produced premature stop codons. The RIPK1 
protein was absent in cells of patients P2, P3 and P4 (Fig. 1D). Therefore, all three 
homozygous mutations led to complete RIPK1 deficiency. The four patients had lymphopenia, 
suffered from recurrent viral, bacterial and fungal infections, early-onset inflammatory bowel 
disease (IBD) involving upper and lower gastrointestinal tract and developed arthritis (Tables 
S1 and S2, fig. S4 and Supplementary Text (2)). Therefore, these clinical features characterize 
RIPK1 deficiency in humans. 
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RIPK1 is a widely expressed cytosolic protein kinase controlling multiple signaling 
pathways leading to inflammation and apoptotic or necroptotic cell death (4, 5). RIPK1 is 
present in protein complexes that mediate signal transduction from cell surface receptors, 
including TNFR1, TLR3 and TLR4 (4, 5). Stimulation of these receptors activates the 
canonical NF-B pathway and the mitogen-activated protein kinases (MAPKs). This leads to 
phosphorylation of NF-B and AP-1 transcription factors, which induces expression of pro-
inflammatory and pro-survival genes (4, 6). To assess the functioning of these signaling 
pathways, we stimulated patients’ skin fibroblasts with TNF and poly(I:C) in vitro. We found 
that phosphorylation of MAPK p38 and the AP-1 subunit cJun was markedly reduced (Fig. 2A 
and fig. S5), while phosphorylation of MAPK p42/44 (ERK2/1) and NF-B p65 was partially 
reduced (fig. S6). TNF-induced secretion of cytokines IL-6 and RANTES by patients’ 
fibroblasts was also diminished (fig. S7). Thus, similar to studies in RIPK1-deficient mice (7-
11), pro-inflammatory signaling downstream of TNFR1 and TLR3 is impaired in the patients. 
We next investigated whether RIPK1 deficiency affected cell viability. After stimulation with 
TNF or poly(I:C), we found significantly fewer viable fibroblasts of patients than those of 
healthy controls (P < 0.001; Fig. 2B). When we transduced patient’s fibroblasts and expressed 
wild-type RIPK1, this viability defect was reversed (fig. S8) and activation of the MAPK and 
NF-B pathways was also rescued (fig. S9).  To investigate the mechanism of cell death, we 
studied patient’s fibroblasts 24 hours after poly(I:C) stimulation and found increased 
phosphorylation of RIPK3 and Mixed Lineage Kinase Domain Like Pseudokinase (MLKL), 
proteins that mediate necroptosis (12, 13) (Fig. 2C). No cleavage of caspase-8 and minimal 
cleavage of caspase-3 were found, indicating that apoptosis was not a major death mechanism 
of these cells (fig. S10). Consistent with these results, MLKL inhibitor Necrosulfonamide and, 
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to a lesser extent, RIPK3 inhibitor GSKʹ872 rescued patient’s cells from poly(I:C)-induced 
death, while pan-caspase inhibitor zVAD-fmk had no effect (Fig. 2D). As expected, RIPK1 
inhibitors Nec-1s and GSK2982772 had no effect on these RIPK1-deficient cells (Fig. 2D). 
To investigate the molecular basis of the immune dysfunction responsible for the 
disease, we studied cytokine release in whole blood assays. After stimulation with 
phytohemagglutinin (PHA), patients’ blood cells produced markedly increased amounts of IL-
1β (Fig. 3A). This enhanced IL-1β response to PHA normalized in patient P2 after 
hematopoietic stem cell transplantation (HSCT) (Fig. 3A). Also, after PHA stimulation 
patients’ blood produced reduced amounts of IL-17 and IFN-, while the production of TNF, 
IL-6 and IL-10 was similar to controls (fig. S11), which shows dysregulated but not generally 
suppressed responses of stimulated T cells. After stimulation with lipopolysaccharide (LPS), 
whole blood of healthy controls produced large amounts of IL-6 and IL-10 and showed 
strongly up-regulated production of TNF and IL-12 upon co-stimulation with LPS and IFN- 
(Fig. 3B). These responses were dramatically reduced in the RIPK1-deficient patients, but 
normalized in patient P2 after HSCT (Fig. 3B). At the same time, we found normal production 
of IL-10, IL-6 and TNF in patients’ whole blood assays after stimulation with TLR1/2 and 
TLR2/6 ligands Pam3CSK4 and Pam2CSK4 (fig. S12), consistent with the RIPK1-
independent signaling downstream of these receptors (4). The production of IL-1β in whole 
blood of the patients was within normal range after LPS stimulation and was slightly reduced 
after LPS and IFN- co-stimulation (fig. S13). Similar to whole blood assays, primary 
monocytes isolated from blood of patient P4 and stimulated with LPS showed reduced 
production of IL-6, TNF and IL-12 (Fig. 3C). However, the production of IL-1 was 
increased (Fig. 3C).  
7 
 
We next analyzed in more detail the response of RIPK1-deficient human immune cells 
to LPS stimulation. We were unable to conduct further studies of primary blood cells from the 
patients because P1 and P3 had died, P2 had undergone HSCT and P4 was not available. We 
therefore used CRISPR-Cas9 technology to knock out RIPK1 in the human monocyte-like 
THP-1 cell line (2). After LPS stimulation, THP-1
RIPK1-/-
 cells secreted reduced amounts of IL-
6 and IL-10 and released increased amounts of IL-1β (Fig. 3D), resembling the cytokine 
response of patients’ cells (Fig. 3C). The impaired cytokine production was preceded by the 
reduced phosphorylation of MAPK p38 (Fig. 3E), mirroring the defective MAPK p38 
phosphorylation in the patients’ primary fibroblasts (Fig. 2A). Activation of NF-B p65 and 
other branches of the MAPK pathway was not affected in the THP-1
RIPK1-/-
 cells (fig. S14). 
Differential activation of the MAPK and NF-B pathways after LPS stimulation was reported 
previously (14), and our results indicate that RIPK1 deficiency in THP-1 cells preferentially 
alters LPS-induced MAPK p38 activation.  
After LPS stimulation, THP-1
RIPK1-/-
 cells showed increased phosphorylation of RIPK3 
and MLKL and enhanced cell death (Figs. 3F and 3G). No cleavage of caspase-8 or caspase-3 
was found (fig. S15). Necrosulfonamide and GSKʹ872, but not zVAD-fmk, reduced death of 
THP-1
RIPK1-/-
 cells (Fig. 3G), again pointing at necroptosis as the main death mechanism of 
these cells. Necroptosis of THP-1
RIPK1-/-
 cells was accompanied by the release of cleaved 
caspase-1 that we found in the supernatant together with IL-1 (Fig. 3H), suggesting 
concurrent activation of inflammasome. Next, we compared mechanisms that mediate IL-1 
release from LPS-stimulated THP-1
RIPK1-/-
 cells with those that mediate IL-1 release during 
pyroptosis of wild-type THP-1 cells stimulated by LPS and Nigericin. We found that different 
mechanisms are at play. After treatment with Necrosulfonamide, IL-1 release during 
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pyroptosis was only slightly reduced, while it was completely prevented in THP-1
RIPK1-/-
 cells, 
suggesting that in these cells IL-1 release is secondary to necroptosis (fig. S16). Of note, 
treatment of THP-1
RIPK1-/-
 cells with Necrosulfonamide did not restore reduced IL-6 secretion 
(fig. S17), indicating that it is reduced not because of enhanced necroptosis, but is an earlier 
phenomenon. Taken together, these data show that human RIPK1-deficient cells have impaired 
pro-inflammatory signaling leading to dysregulated cytokine secretion and are prone to 
necroptosis, which, in myeloid cells, is accompanied by IL-1 release.  
RIPK1 has been extensively studied in mouse models (7-9, 15-18) and its inhibitors are 
considered for the treatment of acute and chronic organ injury, including stroke, myocardial 
infarction and renal ischemia–reperfusion injury (19, 20), but the phenotype associated with 
RIPK1 deficiency in humans was unknown. While the Ripk1-knockout mice displayed 
systemic inflammation and cell death in multiple tissues and died during the postnatal period 
(7-9), the clinical presentation of our RIPK1-deficient patients was less severe. Nevertheless, 
they suffered from immunodeficiency, gut inflammation and progressive polyarthritis. During 
infection, activation of the pattern-recognition receptors TLR3 and TLR4 and stimulation of 
TNFR1 by secreted TNF induces pro-inflammatory effects. Consistent with the established 
role of RIPK1 in the signal-transducing protein complexes assembled downstream of these 
receptors (4-7, 10, 11), we found impaired pro-inflammatory signaling in RIPK1-deficient 
cells and reduced production of multiple cytokines. These defects, as well as lymphopenia, 
likely explain susceptibility to infections in the patients.  
Our data show that LPS stimulation of RIPK1-deficient monocytes resulted in the 
increased necroptosis and IL-1β release, similar to the previous observation in the RIPK1-
deficient monocytes transdifferentiated from immortalized human B cells (21). Furthermore, 
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we found high IL-1 levels after PHA stimulation of the patients’ whole blood. This may 
suggest that IL-1β production by T cells, which was reported recently (22, 23), is also 
increased in the context of RIPK1 deficiency. Alternatively, dysregulated secretion of T cell 
factors after PHA stimulation may have augmented the IL-1β production by patients’ 
monocytes in whole blood. IL-1β is a pro-inflammatory cytokine involved in the pathogenesis 
of arthritis and IBD (24, 25). Another cytokine dysregulated in our patients, IL-10, is essential 
for balancing immune response in the gut and impaired signaling in the IL-10 pathway has 
been associated with IBD (26, 27). Therefore, it is likely that low secretion of IL-10 and 
increased IL-1 production contributed to the pathogenesis of arthritis and IBD in our RIPK1-
deficient patients. Accordingly, treatment with IL-1 inhibitors may be considered in RIPK1 
deficiency, although none of our patients received such therapy. Interestingly, while patients 
P1, P2 and P3 developed severe IBD in the first months of life, P4 had no IBD signs up until 
the age of 4 years. Therefore, genetically determined RIPK1 deficiency was not the sole cause 
of IBD in these patients. Rather, it led to the dysregulated cytokine production, which set the 
immune system in a predisposition mode, while additional factors, e.g. distinct microbiomes, 
likely affected progression to IBD in these patients. This scenario resembles the adult-onset 
IBD, where immune predisposition is determined by multiple common genetic 
polymorphisms, while progression to clinical disease is driven by environmental factors (28). 
The intestinal epithelium provides a physical barrier and participates in maintaining 
immune homeostasis in the gut.  Mice genetically deficient in Ripk1 in the intestinal epithelial 
cells (IEC) developed severe lethal intestinal pathology due to FADD–caspase-8-mediated 
apoptosis of IEC (9, 29). Histological examination of gastrointestinal biopsies from P1 and P2 
showed only occasional cells with apoptotic morphology and cells positive for cleaved 
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caspase-3 (fig. S18). Such cells were also present in biopsies from children with idiopathic 
IBD and histologically normal biopsies (fig. S18). Thus, in contrast to the mouse model, no 
extensive IEC apoptosis was found, suggesting that it is not a characteristic feature of RIPK1 
deficiency in humans. Likewise, skin disorders were not typical in our patients, indicating no 
special protective role of human RIPK1 in keratinocytes, in contrast to mice with epidermis-
specific RIPK1 knockout that developed severe skin inflammation (9, 30). Given that HSCT in 
patient P2 resolved IBD and arthritis and reduced the frequency of infections (2), it is likely 
that dysfunction of the immune system rather than dysfunction of other cell types was critical 
for disease development.   
In summary, our findings indicate that RIPK1 has a more narrow function in humans 
than in mice, with the effects of RIPK1 deficiency being largely confined to the immune 
system. Accordingly, HSCT performed at young age can be an effective treatment in RIPK1-
deficient patients. 
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Fig. 1. Mutations of the RIPK1 gene cause complete RIPK1 deficiency 
(A) Three families with the RIPK1 gene mutations: wt, wild-type allele; mut, mutant allele.  
and  - unaffected;  and  - affected. (B) Patients’ mutations. Locations of deletions are 
shown by red arrows; deleted nucleotides are shown by red frames. Deletion of exon 4 in P4 
(right panel). (C) Domains of the RIPK1 protein. RHIM - Receptor-interacting protein (RIP) 
Homotypic Interaction Motif. Codons affected by mutations are shown by red lines; codon 
numbers and corresponding patients are indicated above. (D) Western blot assays for detection 
of RIPK1 protein in fibroblasts (left panel) and T cell blasts (right panel).  
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Fig. 2. RIPK1-deficient fibroblasts show impaired MAPK signaling and necroptosis 
(A) Primary fibroblasts were stimulated with 50 ng/mL TNF or 100 μg/mL poly(I:C) and 
protein extracts were subjected to immunoblotting (N = 2). (B) Viability of primary fibroblasts 
after stimulation with 100 ng/mL TNF or 20 μg/mL poly(I:C). Experiments were repeated at 
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least three times. Differences between stimulated and unstimulated cells are shown at each 
time point relative to the 0 time point. P-values were calculated using two-tailed unpaired T-
test, comparing combined data from healthy subjects (parent and control) vs patients (P2 and 
P3); graphs show mean values ± SEM. (C) Fibroblasts were stimulated with 20 μg/mL 
poly(I:C) for 24 hours and protein extracts were subjected to immunoblotting (N = 1). (D) 
Fibroblasts of P2 and controls (unrelated and parent A.1) were stimulated with 20 μg/mL 
poly(I:C) for 24 hours in the presence of indicated compounds and cell viability was measured 
(N ≥ 6); graphs show mean values ± SEM. P-values were calculated using two-tailed unpaired 
T-tests. *** P < 0.001.  
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Fig. 3. RIPK1-deficient immune cells show dysregulated cytokine production, impaired 
MAPK signaling and necroptosis  
(A-B) Cytokines were measured in whole blood after 24 hours stimulation using 10 μg/mL 
PHA (A) or 1 μg/mL LPS or 1 μg/mL LPS plus 20,000 IU/mL IFN- (B). To account for 
lymphopenia data were corrected for lymphocyte counts. Controls are shown as grey circles, 
patients as colored circles (P1 – magenta, P3 – blue, P4 – green, P2 before HSCT – red); P2 
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after HSCT – red star.  P-values were calculated using two-tailed Mann-Whitney test, 
excluding the data of P2 after HSCT. (C) CD14+ monocytes were purified from PBMC of 
patient P4 (age 3 y) and a healthy adult (travel control), stimulated overnight with 5 μg/mL 
LPS and then cytokines were measured in supernatants. N = 1, two technical replicates, graphs 
show mean values. (D) THP-1 cells (2 wild-type and 7 THP-1
RIPK1-/-
 clones) were treated with 
50 ng/mL phorbol 12-myristate 13-acetate (PMA) for 3 days, rested for 1 day and stimulated 
overnight with 5 g/mL LPS. Cytokines were measured in supernatants. The data were 
corrected for the estimated number of live cells and show means combining data for different 
clones ± SEM. P-values were calculated using two-tailed unpaired T-test. (E) THP-1 cells 
were treated with PMA as in (D), stimulated with 1 μg/mL LPS and the extracted proteins 
were analyzed by immunoblotting (N = 2). (F) THP-1 cells were stimulated with 5 μg/mL LPS 
for 48 hours and the extracted proteins were analyzed by immunoblotting (N = 2). (G) THP-1 
cells were stimulated with 5 μg/mL LPS for 48 hours in the presence of indicated compounds 
and cell death was measured using lactate dehydrogenase (LDH) release assay (N ≥ 4). The 
data show means ± SEM. P-values were calculated using two-tailed unpaired T-test. (H) 
Supernatants of THP-1 cells studied in (F) were analyzed by immunoblotting (N = 1). * P < 
0.05, ** P < 0.01, *** P < 0.001.   
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Materials and Methods 
 
Primary immunodeficiency (PID) patients 
The PID cohort consisted of 48 patients that suffered severe and/or disseminated and/or 
recurrent bacterial and/or viral infections and have been diagnosed with common variable 
immunodeficiency (CVID), specific antibody deficiency with poor vaccine responses, 
combined T and B-cell immunodeficiencies, phagocyte and innate immunity defects, as well as 
undefined PIDs. The nature and possible consequences of the study were explained to the 
participants and all material was obtained with informed consent in accordance with the 
Declaration of Helsinki and with approvals from the ethics committees (04/Q0501/119, 
10/H0906/22 and 15/WS/0019).  
 
Exome sequencing and bioinformatics analysis 
We isolated DNA samples from blood or peripheral blood mononuclear cells (PBMCs). 
Library preparation, exome capture and sequencing have been done according to the 
manufacturers’ instructions. For exome target enrichment Agilent SureSelect 38 Mb kit was 
used. Sequencing was done using Illumina HiSeq 2000. FASTQ files were aligned to the hg19 
reference sequence using Novoalign version 2.07.19, including hard and soft clipping, quality 
calibration and adapter trimming. Duplicate reads were excluded using the PICARD tool 
MarkDuplicates. Calling was performed using SAMtools v0.18 and single sample calling. The 
resulting calls were annotated with the software ANNOVAR. Candidate variants were filtered 
based on function: loss-of-function, non-synonymous or potential splicing altering variants 
(defined as being with 5 bp of the actual splice site) and frequency. To identify rare variants, 
we excluded known polymorphisms previously detected in 1000 Genomes (31) and 6,500 
exomes (32). To identify large deletions and duplications we used software ExomeDepth (33) 
(http://cran.r-project.org/web/packages/ExomeDepth/index.html). 
 
RIPK1 gene mutations sequencing  
To study the RIPK1 gene mutations by Sanger sequencing we first used primers 
5’CTTTGCCCACAGATTGAGGT3’ and 5’TGAAGGAGAAATGGGTCCAG3’ to amplify 
gene region with the 4-nucleotide deletion and primers 5’TTTCCTGGGCGACATTTTAC3’ 
and 5’ACCCTGGAATTTCACAGCAC3’ to amplify gene region with the 21-nucleotide 
deletion. We then sequenced the amplicons using one of the primers. 
To study deletion of the RIPK1 exon 4 we used PCR with flanking primers 
5’TGGAAAAGGCGTGATACACA3’ and 5’TGGCCTGTTCCCAGATTTTA3’ and ran PCR 
products on an agarose gel. 
 
To sequence cDNA of P3, initially total RNA was extracted using RNeasy mini kit (74106, 
Qiagen) from primary dermal fibroblasts of P3. Then, cDNA was generated using Maxima 
Reverse Transcriptase (EP0741, Thermo Scientific) and oligo(dT)18 primers (S0132, Thermo 
Scientific) according to manufacturer recommendations. Part of the RIPK1 cDNA was 
amplified using primers 5’CTGAATGACGTCAACGCAAA3’ and 
5’AGGCTGTTCTGTGGCTGAAT3’ and then sequenced using one of the primers. 
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Cells 
Human primary dermal fibroblasts of patients, a heterozygous parent (A.1), and a healthy adult 
control (HDFa, C0135C, ThermoFisher Scientific, UK) as well as 293T cells were cultured in 
DMEM (61965-026, Gibco, Life Technologies, UK) supplemented with 10% heat-inactivated 
fetal bovine serum (FCS-SA/500, Labtec), 20 M HEPES buffer (H0887, Sigma, UK), and 
100 U/mL penicillin and 100 µg/mL streptomycin (P0781, Sigma, UK).  
 
THP-1 cells were cultured in RPMI medium 1640 (21875, Gibco, life technologies, UK) with 
10% heat-inactivated fetal bovine serum, 20 M HEPES buffer, and 100 U/mL penicillin and 
100 µg/mL streptomycin. When PMA differentiation was used, THP-1 cells were plated at 5 x 
10
4
 cells per well in 96 well plates and cultured for 3 days with 50 ng/mL PMA (Calbiochem, 
524400), washed 3 times with PBS and cultured for an additional day in media without PMA 
before been treated as required.  
 
Human PBMC were isolated from fresh peripheral blood by centrifugation with a gradient of 
Ficoll-paque Plus (17-1440-03, GE Healthcare, UK) at 2000 rpm for 23 minutes at room 
temperature. Buffy coat layer containing PBMC was washed with PBS 3 times. Monocytes 
were isolated by magnetic cell sorting using anti-CD14-coated beads (130-050-201, Miltenyi 
Biotec, UK). Monocytes were cultured in RPMI medium 1640 (21875, Gibco, life 
technologies, UK) with 10% heat-inactivated fetal bovine serum, 20 M HEPES buffer, 
penicillin (100 U/ml) and streptomycin (100 µg/ml) in 48 well plates (2.8 x 10
5
 cell in 250 L 
per well) for 16 hours.  
 
To generate T blasts, frozen monocyte-depleted PBMCs of patient P4 and its travel control 
were stimulated with Dynabeads Human T-Activator CD3/CD28 (11161D, ThermoFisher), 1 
bead per cell, followed by 4 days resting in the presence of 100 U/mL IL-2.  
 
Cloning  
cDNA from primary fibroblasts of a healthy subject was amplified by PCR using the following 
primers:  
Hind_RIPK1_cDNA_Fw   5’CCCAAGCTTATGCAACCAGACATGTCC3’; 
Xho_RIPK1_cDNA_Rv    5’CCGCTCGAGGTTCTGGCTGACGTAAATCAAG3’. A 
HindIII/XhoI double digested insert was sub-cloned into pcDNA6/myc-His A (#V22120, 
ThermoFisher). To generate a lentiviral vector that ensures expression in primary cells, 
pLJM1-EGFP (#19319, AddGene) was engineered by replacing the CMV promoter with the 
human elongation factor 1α (EF1α) promoter (34). The pcDNA6 construct served as a template 
for PCR amplification to introduce the FLAG-tag at the N-terminus of the RIPK1 protein 
(NheI_FLAG-RIPK1_Fw, 5’-CTAGCTAGC atg GACTACAAAGACGAT 
GACGACAAGCAACCAGACATGTCCTTGAATG – 3’; EcoRI_RIPK1_Rv, 
5’CCGGAATTC tta TTCTGGCTGACGTAAATCAAGCTGC3’. The NheI/EcoRI double 
digested fragment was finally cloned into pEF1α-Lenti-EGFP, in place of EGFP. No mutations 
were found by Sanger sequencing. 
 
Transduction of primary fibroblasts 
The lentivirus stocks were prepared by transient transfection of 3 million 293T cells with the 
envelope plasmid pCMV-VSV-G (1 μg, AddGene #8454), the packing plasmid psPAX2 (1.4 
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μg, AddGene # 12260) and the expression plasmid pEF1α-Lenti -GFP or pEF1α-Lenti -FLAG-
RIPK1 (2 μg) along with 13.5 µL of the transfection reagent Lipofectamine 2000 (#11668019, 
ThermoFisher) following the manufacturer’s instructions.  The following morning the media 
was replaced. The medium was harvested at 48 hours post transfection, cleared by low-speed 
centrifugation (1200 rpm, 5 min), and filtered through 0.45 µm pore size filters. Fresh 
collected virus stocks were used for transduction experiments. Transductions of the patient and 
control fibroblasts were carried out by infection in the presence of 8 µg/ml of Polybrene 
(107689, Sigma). 48 hours later the virus-containing media was replaced by fresh media 
containing 1 µg/mL of puromycin. Two to 3 days later the selected positive transduced cells 
were amplified and kept in the presence of 0.25 µg/mL of puromycin. 
 
Generation of the RIPK1-knockout THP-1 cells 
First, LentiCas9-Blast vector (Addgene, plasmid #52962) was used to generate THP-1 cells 
stably expressing Cas9. Lentiviral particles were produced as described above and then used to 
transduce THP-1 cells that were seeded at 5 x 10
4 
cells/mL. Two days post-transduction, the 
cells were subjected to blasticidin selection at a concentration of 5 µg/mL for 7 days. Surviving 
cells were subjected to limiting dilution and plated in 96-well cell plates to obtain single clones 
stably expressing Cas9. After approximately 3 - 4 weeks of clonal expansion, clones were 
screened for Cas9 expression level by western blotting. Clones expressing Cas9 were then 
selected and expanded. 
 
Then, a guide RNA (gRNA) targeting unique sequence of the RIPK1 exon 2 was designed: 
CTTCCTCTATGATGACGCCCAGG. This guide was cloned into the BsmBI unique site of 
the LentiGuide-Puro plasmid (Addgene plasmid #52963). The constructed vector was used to 
produce lentiviral particles as described above. The Cas9-expressing THP-1 cells were then 
transduced and 48 hours later the media was replaced by fresh media containing 3 g/mL of 
puromycin. Two weeks later, puromycin-resistant cells were seeded as single cells into 96-well 
plates for clonal expansion in the presence of conditional media (25%), high serum (20%) and 
anti-oxidants (20 nM BCS and 50 μM 1-Thioglycerol, B1125 and M6145, Sigma). After 
expansion, efficient knockout of the RIPK1 gene in each isolated single-cell clone was 
confirmed by western blotting analyzing RIPK1 protein expression. In the following 
experiments we analyzed RIPK1-knockout (RIPK1
-/-
) clones and treated them as biological 
replicates. 
 
Western blotting 
Unstimulated or stimulated fibroblasts, THP-1 cells or T blasts were lysed with ice-cold RIPA 
lysis buffer x2 (R0278, Sigma) supplemented with proteasome inhibitor (cOmplete Mini, 
Roche, 11836153001) for 15 min.  Lysates were centrifuged at 13,000 rpm for 10 min at 4°C. 
Three microliters of the supernatant were used to quantify the proteins (23227, BCA assay kit, 
Pierce) as recommended by the supplier. The remaining supernatant was incubated with x2 
Laemmli sample buffer (BIO-RAD, 161-0737), containing 2-mercaptoethanol (Sigma M7522), 
at 100°C for 5 min.  7.5-40 μg of proteins were resolved on 10% or 12% Acrylamide/bis gels 
(161-0173 and 161-0175, BIO-RAD) and transferred to PVDF membranes (170-4159, BIO-
RAD) using the trans-blot turbo transfer system (1704150, BIO-RAD) and probed with the 
following antibodies: RIPK1 (Cell Signaling, #3493, 1 in 1,000 dilution; targeting epitope 
around Leu190);  β-Actin (Sigma, A5441, 1 in 50,000 dilution); NF-κB p65 (Cell Signaling, 
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#4764, 1 in 1000 dilution); Phospho-NF-κB p65 (Cell Signaling, #3033, 1 in 1,000 dilution); c-
Jun (Cell Signaling, #9165, 1 in 1,000 dilution); Phospho-c-Jun II (Cell Signaling, #9261, 1 in 
1,000 dilution), p38 MAPK (Cell Signaling, #9219S, 1 in 1,000 dilution); Phospho-p38 MAPK 
(Cell Signaling, #4511S, 1 in 1,000 dilution); p42/44 MAPK (Cell Signaling, #4696S, 1 in 
2,000 dilution); Phospho-p42/44 MAPK (Cell Signaling, #4370P, 1 in 1,000 dilution); IĸBα 
(Cell Signaling, #4814, 1 in 1000 dilution); Phospho-IKKα/β (Cell Signaling, #2697, 1 in 1000 
dilution); MLKL (Abcam, ab183770, 1 in 1,000 dilution); Phospho-MLKL (Abcam, 
ab187091, 1 in 1,000 dilution); RIPK3 (Cell Signaling, #13526, 1 in 1000 dilution); Phospho-
RIPK3 (Cell Signaling, #93654, 1 in 1000 dilution); caspase-1 (p20) (AdipoGen Life Sciences, 
AG-20B-0048, 1 in 1000 dilution); caspase-3 (Cell Signaling, #9662, 1 in 1000 dilution); 
caspase-8 (Cell Signaling, #9746, 1 in 1000 dilution); IL-1β (R&D SYSTEMS, AF-201-NA, 1 
in 1000 dilution) and GFP (Abcam, ab290, 1 in 1,000 dilution). Band densitometry was 
determined by ImageJ. 
 
To study proteins released in supernatants, THP-1 cells were stimulated either with 5 μg/mL 
LPS for 48 hours or co-stimulated with 5 μg/mL LPS for 48 hours and 20 μM Nigericin 
(InvivoGen, NIG-38-02) for the last 90 minutes. To extract proteins, cell supernatants were 
collected and subjected to protein precipitation using methanol (v/v). Western blotting was 
then performed as described above. 
 
Cell viability/proliferation and LDH release assays 
Fibroblasts were seeded in completed media without antibiotics at 10,000 cells per well in 96-
well plates in duplicates. The following day (0 time point), the cells were washed 3 times using 
PBS and treated with 100 μL of starving media without antibiotics supplemented with TNFα 
(final concentration 100 ng/mL) or poly(I:C) (final concentration 20 μg/mL) in the presence or 
absence of zVAD-fmk (BD Biosciences, 550377, final concentration 20 μM), Nec-1s (7-Cl-O-
Nec-1, Calbiochem, 504297, final concentration 10 μM), GSK2982772 (Axon, 2713, final 
concentration 1μM), Necrosulfonamide (Calbiochem, 480073, final concentration 0.5 μM), 
GSK’872 (Calbiochem, 530389, final concentration 1.5 μM). DMSO (Sigma, D2438, 0.1 
μg/mL) was used as a negative control. Metabolic activity of live cells was assessed at 0, 24 
hours, 48 hours and 72 hours post treatment using the Promega CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay (G5421) according to the manufacturer’s instructions. 
Each result was an average of two measurements. Statistical analysis was done using an 
unpaired two-tailed T-test assuming equal variance comparing cells of patients and controls. 
 
The wild-type THP-1 cells (two parental Cas9-expressing THP-1 cell clones) and the RIPK1
-/-
 
THP-1 cell clones were seeded at 50,000 cells per well in 96 well plates in triplicates in 
completed media. Cells were stimulated with crude LPS (final concentration 5 μg/mL) in the 
presence or absence of zVAD-fmk (final concentration 20 μM), Nec-1s (final concentration 10 
μM), GSK2982772 (final concentration 1μM), Necrosulfonamide (final concentration 0.5 μM), 
GSK’872 (final concentration 3 μM). DMSO (Sigma, D2438, 0.1 μg/mL) was used as a 
negative control. Cell death was calculated by measuring Lactate Dehydrogenase (LDH) in cell 
supernatants using CytoTox 96 (non-radioactive cytotoxicity assay, Promega, G1780). The 
absorbance was recorded at 490 nm using a micro-plate reader. The basal level of LDH release 
was determined with 40 μL supernatant from media and the maximal LDH release was 
determined with 40 μL supernatant from lysed non treated cells. The calculation of the 
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percentage of LDH release was as follows: 100 * (LDH release from treated group minus basal 
release) / (maximal LDH release minus basal release). Each result was an average of three 
measurements. Statistical analysis was done using an unpaired two-tailed T-test assuming 
equal variance comparing the wild-type THP-1 clones against the THP-1
RIPK1-/-
 clones. 
 
Cytokine production assays  
Whole blood was diluted 1:5 in RPMI into 96-well F plates (Corning) and activated by single 
stimulation with phytohemagglutinin (PHA; 10 μg/ml; Sigma-Aldrich), LPS (1 μg/ml, List 
Biochemicals) or co-stimulating with LPS and IFN- (2 x 104 IU/mL, Imukin, Boehringer 
Ingelheim), Pam2CSK4 (1 g/mL) or Pam2CSK4 (1 g/mL) plus IFN- (2 x 104 IU/ml), 
Pam3CSK4 (1 g/mL) or Pam3CSK4 (1 g/mL) plus IFN- (2 x 104 IU/ml). Supernatants 
were taken after 24 hours. Cytokines were measured using standard ELISA according to the 
manufacturer’s recommendations (IFN-, Pelikine, Sanquin, NL), or multiplexed (TNF, IL-
12, IL-10, IL-6, R+D Systems Fluorokinemap) on a Luminex analyzer (Bio-Plex, Bio-Rad, 
UK). Statistical analysis was done using two-tailed Mann-Whitney tests. Supernatants from 
primary monocytes, fibroblasts or THP-1 cells were collected 16-24 after treatment and 
cytokine amounts were measured using ELISA, as above. Statistical analyses were done using 
two-tailed unpaired T tests assuming equal variance. 
 
Immunohistochemistry 
Immunohistochemical staining of patient and control gastrointestinal biopsies was performed 
on formalin-fixed paraffin-embedded tissue sections using the Ventana Discovery Ultra 
automated platform. The following antibodies were used: cleaved caspase-3 (R&D Systems, 
rabbit monoclonal antibody, 269518), CD3 (Leica, mouse monoclonal antibody, LN10), and 
cytokeratin (Ventana, mouse monoclonal antibody cocktail, AE1/AE3 and PCK26). Antigen 
retrieval used the Ventana CC1 cell conditioning buffer and diaminobenzidine (DAB) 
detection used Ventana ultraView reagents. 
  
27 
 
Supplementary Text 
 
Clinical and immunological findings in patients P1 – P4 
In family A, parents were first cousins of Pakistani descent living in the UK. They had two 
affected male children, P1 and P2; two male siblings and one female sibling were healthy (Fig. 
1A). In the first months of life P1 was diagnosed with perinatal human cytomegalovirus 
(HCMV) infection, had enteropathy with diarrhea, vomiting, hepatosplenomegaly, and failure 
to thrive. He developed recurrent mouth ulcers and perianal abscesses. Biopsies taken in the 
first year of life showed gastritis, partial villous atrophy in the duodenum and mild active 
chronic inflammation in the colon. Biopsies taken at the age of 4 and 12 years showed active 
chronic gastritis, mild chronic duodenitis and focally ulcerative active chronic inflammation in 
the colon (fig. S4A-C), indicating inflammatory bowel disease (IBD). Beginning in early 
childhood, he suffered from recurrent oral and perianal candidiasis and recurrent respiratory 
infections. Mycobacterium avium intracellulare was grown from sputum of P1 on one 
occasion at the age of 4 years. At 8 years of age he developed progressive erosive polyarticular 
arthritis. By the age of 9 years, he was diagnosed with chronic lung disease, bronchiectasis, 
and Pseudomonas aeruginosa colonization. Lung function tests showed forced expiratory 
volume FEV1 and forced vital capacity (FVC) at 50-60% of normal. At the age of 11 years P1 
had severe pneumonia caused by varicella zoster virus (VZV), necessitating admission to 
pediatric intensive care. At the age of 11 years he developed an urticarial skin rash and skin 
biopsy showed dermal lymphocytic vasculitis. Variable T cell lymphopenia and reduced 
numbers of NK cells were found (Table S2). T cell proliferation in response to mitogens, 
neutrophil oxidative burst and levels of immunoglobulins were normal.  
Patient P2, a younger brother of P1, also had hepatosplenomegaly and enteropathy with 
diarrhea, perianal abscesses and anal fistula in the first months of life. Endoscopy showed IBD 
with persistent active chronic inflammation in the stomach, duodenum and colon (fig. S4D-F). 
He suffered from multiple respiratory infections, including severe respiratory syncytial virus 
(RSV) bronchiolitis. By the age of 32 months diarrhea continued, he developed polyarthritis, 
and was diagnosed with bronchiectasis. Immunological analysis showed variable CD4+ T 
lymphopenia, normal T cell proliferation in response to mitogens, normal levels of 
immunoglobulins and normal neutrophil oxidative burst (Table S2). 
In family B, the parents were first cousins of the Arabic descent living in Saudi Arabia 
(Fig. 1A). They had 10 children, of which 3 daughters died at the age of 6 to 12 months with 
profuse bloody diarrhea. Patient P3, also female, presented with intractable inflammatory 
enteropathy with bloody diarrhea and mouth ulcers starting soon after birth. Her symptoms 
were only partly controlled by oral and intravenous pulses of prednisolone and anti-TNF 
therapy (adalimumab). At the age of four years she developed a perianal abscess requiring 
surgical drainage. Endoscopic and histological abnormalities were found throughout the bowel 
involving esophagus, stomach, small and large intestine with active inflammation 
characterized by microulceration of the superficial epithelium, cryptitis and crypt abscesses 
(fig. S4H). T lymphopenia developed from the 1
st
 year of life. She also suffered from a non-
erosive inflammatory arthritis affecting hips, elbows, knees, wrists and ankles. From the age of 
11 years P3 suffered from recurrent HSV infections, which led to a non-granulomatous 
inflammation and complete destruction of her nasal septum. At the age of 13 years she suffered 
from pneumonia and Aspergillus flavus was isolated from a bronchoalveolar lavage fluid. Her 
growth was below the 0.4
th
 centile for her age. At this age laboratory investigations revealed 
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generalized lymphopenia and hypogammaglobulinemia (Table S2). Neutrophil oxidative burst 
test was normal. 
In family C, the parents were first cousins of the Arabic descent living in Saudi Arabia. 
At the age of 4 months patient P4, a female, had severe RSV bronchiolitis requiring PICU 
admission. Since then she had recurrent discharging otitis media treated with antibiotics and 
mild occasional diarrhea. IVIG was started at the age of 5 months. While P4 was on IVIG, 
otitis became less frequent. The patient displayed a failure to thrive, which continued at the age 
of 26 months despite high caloric diet. At the age of 2 years she developed arthritis of small 
joints of hand and knee that improved after treatment with non-steroidal anti-inflammatory 
drugs. Initially, she had T and NK lymphopenia, which normalized later (Table S2). Genetic 
analysis discovered RIPK1 deficiency in P4 when she was 3 years old. Given the history of 
IBD in other RIPK1-deficient patients, endoscopy was performed on P4. Normal mucosa was 
found in the esophagus, stomach and duodenum. Colonoscopy showed normal mucosa, except 
telangiectasia at a localized area in the descending colon. There was no bleeding. Colon biopsy 
showed normal mucosa. Thus, at the age of 3 years P4 had no IBD signs. However, at the age 
of 4 years P4 developed chronic bloody diarrhea with anal fissure and perianal fistula. Biopsy 
of rectal mucosa showed granulation tissue, indicative of ulceration, and chronic inflammation 
(fig. S4I). Therefore, P4 progressed to develop IBD, similarly to the other three patients.  
None of the patients was treated with IL-1 inhibitors, e.g. anakinra or canakinumab. 
Hematopoietic stem cell transplantation (HSCT) was performed in patients P1, P2 and P3. P1 
received a transplant from a 10/12 HLA-matched unrelated donor. He died at the age of 12 
years, six weeks after HSCT, due to multiorgan failure including cardiac, respiratory and renal 
dysfunction, and encephalopathy. P3 died at the age of 13 years, three weeks after HSCT, due 
to disseminated HSV and adenovirus infections despite peri-transplant prophylaxis with 
aciclovir for HSV and cidofovir for adenovirus. P2 had HSCT from an 11/12 HLA-matched 
unrelated donor at the age of 30 months. Five years post-HSCT he is developing well with 
100% donor chimerism in all three tested lines (myeloid CD15+, T cell CD3+ and B cell 
CD19+). His weight is on the 50
th
 centile, he has no diarrhea, his perianal abscesses have 
healed and endoscopy showed significant improvement of gut mucosa and no inflammation 
(fig. S4G). There is no active on-going arthritis. However, P2 remains on antibiotic 
prophylaxis because of the chronic lung disease and bronchiectasis.  
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Table S1. Summary of clinical phenotype of patients with complete RIPK1 deficiency  
 
HCMV - human cytomegalovirus; HSCT - hematopoietic stem cell transplantation; HSV-1 - herpes simplex virus 1; IVIG - 
intravenous immunoglobulin; RSV - respiratory syncytial virus; IBD - inflammatory bowel disease; VZV - varicella-zoster virus. 
  
Patient 
(year of birth / 
gender) 
Family 
(ethnic origin) 
Infections Arthritis, age of 
onset 
IBD, 
age of onset 
Lymphopenia Outcome (age 
at HSCT) 
P1 
(1998 / M) 
Family A 
(Pakistani) 
Recurrent respiratory infections, 
bronchiectasis, persistent HCMV, 
VZV pneumonia, lung infections 
with M. avium intracellulare, P. 
aeruginosa, recurrent oral and 
perianal candidiasis 
Polyarthritis, 9 y First months 
of life 
T and NK cell 
lymphopenia 
Died post-
HSCT (12 y)  
P2 
(2009 / M) 
Family A 
(Pakistani) 
Multiple respiratory infections, 
severe RSV bronchiolitis 
Polyarthritis, 2 y First months 
of life 
CD4+ T 
lymphopenia 
Alive and 
well 5 years 
post-HSCT (2 
y 6 m) 
P3 
(1998 / F) 
Family B 
(Arabic) 
Recurrent HSV1 infections, 
Aspergillus pneumonia 
Polyarthritis, 4 y First months 
of life 
T lymphopenia  
(1 y); T, B and 
NK lymphopenia 
(13 y) 
Died post-
HSCT (13 y)  
P4 
(2013 / F) 
Family C 
(Arabic) 
Severe RSV bronchiolitis, 
recurrent otitis media  
Arthritis of small 
joints of hand and 
knee, 2 y 
4 y T, B and NK 
lymphopenia    
(3 m) 
Alive, on 
IVIG 
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Table S2.   Immunological data of the RIPK1-deficient patients  
Patient (age) P1 (11 years) P1 (12 years) P2 (8 months) P2 (2 years) P3 (13 years) P4 (3 months) P4 (2 years) 
Cell subsets, cells/μl (normal ranges)       
Neutrophils 
5,650 
(1,800-7,700) 
 11,300 
(1,500-8,500) 
3,290 
(1,500-8,500) 
2,600 
(1,800-7,700) 
15,140 ↑ 
(1,000-8,500) 
4,070 
(1,500-8,500) 
Monocytes 
430 
(200-800) 
 1,250 
(700-1,500) 
800 
(700-1,500) 
1,060 
(100 – 1,300) 
1,450 
(700-1,500) 
1,020 
(700-1,500) 
Lymphocytes 699 ↓ 
(1,400-4,200) 
1,327  ↓ 
(1,400-4,200) 
2,900 
(1,800-18,700) 
3,890 
(1,400-5,500) 
420 ↓ 
(1,400-4,200) 
1,006   ↓ 
(3,400-12,200) 
3,100 
(1,400-5,500) 
T cells 414 ↓ 
(850-3,200) 
1,049 
(850-3,200) 
1,423 
(1,400-11,500) 
2,056 
(850-4,300) 
220 ↓ 
(850-3,200) 
630      ↓ 
(2,200-9,200) 
2,300 
(850-4,300) 
CD4+  T cells 185 ↓ 
(400-2,100) 
446 
(400-2,100) 
898    ↓ 
(1,000 -7,200) 
1,052 
(500-2,700) 
53   ↓ 
(400-2,100) 
430      ↓ 
(1,600-6,500) 
1,400 
(500-2,700) 
CD8+  T cells 198 ↓ 
(300-1,300) 
537 
(300-1,300) 
433 
(200-5,400) 
793 
(200-1,800) 
111 ↓ 
(300-1,300) 
160      ↓ 
(300-3,400) 
600 
(200-1,800) 
CD4+  naïve T cells 79   ↓ 
(200-1,700) 
231 
(200-1,700) 
626    ↓ 
(800-7,600) 
740 
(300-2,300) 
17   ↓ 
(200-1,700) 
  
CD4-  naïve T cells 62   ↓ 
(78-640) 
168 
(78-640) 
313 
(150-3,200) 
678 
(53-1,100) 
58   ↓ 
(78-640) 
  
CD4-  effector T cells 29 
(16-810) 
105 
(16-810) 
0        ↓ 
(8-1,400) 
0        ↓ 
(24-590) 
0     ↓ 
(16-810) 
  
NK cells 28   ↓ 
(92-1,200) 
38  
(92-1,200) 
529 
(68-3,900) 
347 
(61-510) 
29   ↓ 
(92-1,200) 
40        ↓ 
(97-1,990) 
210 
(61-510) 
B cells 253 
(120-740) 
231 
(120-740) 
1,133 
(130-6,300) 
1,477 
(180-1,300) 
24   ↓ 
(120-740) 
390      ↓ 
(520-2,300) 
520 
(180-1,300) 
T cell proliferation to PHA normal  normal  normal low, 58%  
Serum immunoglobulins, g/L (normal ranges)       
IgM 0.5 (0.5-1.8) 0.53 (0.5-1.8) 1.5 (0.6-2.1) 0.91 (0.4-1.8) < 0.1 (0.5-1.8) 1.6 (0.6-2.1) 1.4 (0.4-1.8) 
IgG 12.8 (4.9-16.1) 16.5 (4.9-16.1) 9.4 (3.0-10.9) 8.0  (4.5-9.1) 8.68* (4.9-16.1) 5.2 (3.0-10.9) 6.3* (4.5-9.1) 
IgA 1.9 (0.7-2.5) 3.28 (0.7-2.5) 0.97 (0.4-2.0) 0.65  (0.2-1.0) < 0.07 (0.7-2.5) 0.4 (0.4-2.0) 0.8 (0.2-1.0) 
Specific antibodies (normal ranges)       
Tetanus, IU/mL 0.2(0.1-10)  2.5 (0.1-10)   0.003 ↓(0.1-10)  
Haemophilus influenza B, mg/L 0.2 ↓(1-20)  9 (1-20)   0.64   ↓(1-20)  
Pneumococcus, mg/L 19(20-200)  75 (20-200)     
* on immunoglobulin replacement therapy; PHA – phytohemagglutinin. Values below normal ranges are shown in bold. 
Normal ranges for T lymphocyte subsets are from (35)
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Fig. S1. Mutation found in patient P3 
(A) Schematic presentation of the mutation. DNA sequences of the RIPK1 exons 4 and 5 are 
shown in upper case; DNA sequence of intron 4 is shown in lower case. The 21-nucleotide 
deletion in the patient’s DNA is highlighted in yellow, including one base of exon 4 and 
twenty bases of intron 4. The 48-nucleotide insertion from intron 4 in the patient’s cDNA is 
highlighted in green. The activated cryptic slice site in intron 4 is shown in red. Irrelevant part 
of intron 4 is shown by dots. 
(B) Electropherogram of the patient’s cDNA showing sequences matching to exon 4 
(excluding one last nucleotide A), 48-nucleotide insertion from intron 4 and then exon 5. 
  
 
A 
 
Exon 4           intron 4              Exon 5   
 
                              21 nt deletion         48 nt insertion from intron 4 
ATATTTGCAAATAAGGAGCCATATGAAAgtaaggcattacttactttccactgccgtcccctcagcatctacacgcactgtgcctggaactaataggt....agATGCTATCTGTGAGCAGCAGTT 
 
 
 
 
B 
 
Exon 4              48 nt insertion from intron 4         Exon 5    
 
 
 
 
 
A T A T T T G C A A A T A A G G A G C C A T A T G A A C A C T G C C G T C C C C T C A G C A T C T A C A C G C A C T G T G C C T G G A A C T A A T A G A T G C T A T C T G T G A G C A G C A G T T
270280290300310320330340350
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Fig. S2. Mutation found in patient P4 
Electropherogram of the patient’s DNA with sequences matching to introns 3 and 4 showing a 
2,064-nucleotide deletion. Nucleotide positions of the deletion breakpoints in the GRCh38 
genome build are shown below.  
C T G
880
T T G A G A A G T C
890
G C T G T T T G A C
900
A T A A T C T T T T
910
G T T C A T C A C C
920
A
GRCh38      Chr 6         3,082,951                        3,085,016 
intron 3                                                                intron 4 
exon 4 
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Fig. S3. PCR flanking the 2,064-nucleotide deletion found in family C 
Gel electrophoresis shows an amplicon of the expected size in control; a shorter amplicon due 
to deletion is present in patient P4; both amplicons are present in heterozygous parents. del – 
deletion, wt – wild type. 
 
  
expected amplicon
4,266 bp
shorter amplicon
2,202 bp
Genotype:  del/del      del/wt del/wt wt/wt
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Fig. S4. Gastrointestinal tract biopsies of patients P1- P4 
Hematoxylin and eosin staining. 
(A) Stomach of P1showing active chronic inflammation including a prominent lymphoid 
aggregate in the gastric mucosa (asterisk). Scale bar = 200 μm. 
(B) Colon of P1 showing active chronic inflammation with patchy ulceration (asterisk). Scale 
bar = 200 μm. 
(C) Colon of P1 showing active chronic inflammation with large lymphoid aggregates in 
mucosa and submucosa (asterisk). Scale bar = 200 μm. 
(D) Rectum of P2 showing chronic inflammatory changes including branching crypts, fibrosis 
and Paneth cell metaplasia. There is an increase in chronic inflammatory cells and foci of acute 
inflammation (arrow). Scale bar = 200 μm. 
(E) Duodenum of P2 showing marked villous atrophy, crypt hyperplasia and an increase in 
chronic inflammatory cells in the lamina propria. Scale bar = 200 μm. 
(F) Duodenum of P2 at higher magnification showing patchy acute inflammation of crypt 
epithelium (arrow). Scale bar = 50 μm. 
(G) Duodenum of P2, 10 months after HSCT, showing a substantially improved villous 
architecture with no significant inflammation. Scale bar = 200 μm. 
(H) Small intestine of P3 showing distortion of villous architecture with short and blunted villi 
and patchy crypt hyperplasia. A focal increase in acute inflammatory cells was observed. Scale 
bar = 200 μm. 
(I) Rectum of P4 showing granulation tissue (asterisk), indicative of ulceration, overlying 
mucosa showing mild chronic inflammatory changes. Scale bar = 200 μm.  
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Fig. S5. RIPK1-deficient fibroblasts show reduced phosphorylation of MAPK p38 and 
cJun 
Primary fibroblasts were stimulated with 50 ng/mL TNF or 100 μg/mL poly(I:C) and protein 
extracts were subjected to immunoblotting as shown in Fig. 2A. Bar graphs show fold change 
of band densitometry. N shows the number of independent experiments. Graphs show mean 
values ± SD. 
 
  
TNFα
Poly(I:C) 
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Fig. S6. RIPK1-deficient fibroblasts have partially reduced phosphorylation of MAPK 
p42/44 (ERK1/2) and p65 subunit of NF-B 
Primary fibroblasts were stimulated with 50 ng/mL TNF or 100 μg/mL poly(I:C) and protein 
extracts were subjected to immunoblotting. Bar graphs show fold change of band 
densitometry. N shows the number of independent experiments. Graphs show mean values ± 
SD. 
  
TNFα 
Poly(I:C) 
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Fig. S7. RIPK1-deficient fibroblasts show reduced production of IL-6 and RANTES after 
TNF stimulation 
Primary fibroblasts of a healthy unrelated control, a healthy parent (A.1) and patients P2 and 
P3 were stimulated overnight with 100 ng/mL TNF. Cytokines IL-6 and RANTES were 
measured in supernatants by ELISA (N=3). The data were corrected for the estimated number 
of live cells and show means ± SEM. P-values were calculated using two-tailed unpaired T-
test. ** P < 0.01 
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Fig. S8. Forced expression of RIPK1 reverses viability defect in patient’s fibroblasts 
Fibroblasts of P3 were transduced with lentiviral constructs expressing either RIPK1 or green 
fluorescent protein (GFP). Protein extracts were subjected to immunoblotting to determine 
levels of RIPK1 and GFP expression (left panel). Next, viability of the transduced fibroblasts 
was determined after stimulation with 50 ng/mL TNF (center panel, N = 2) or 20 μg/mL 
poly(I:C) (right panel, N = 5). Differences between stimulated and unstimulated cells are 
shown at each time point relative to the 0 time point. P-values were calculated using two-tailed 
unpaired T-test; graphs show mean values ± SEM.  
* P < 0.05, ** P < 0.01. 
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Fig. S9. Forced expression of RIPK1 rescues impaired MAPK and NF-B activation in 
patient’s fibroblasts 
Fibroblasts of P3 were transduced with lentiviral constructs expressing either RIPK1 or green 
fluorescent protein (GFP). Next, cells were stimulated with 50 ng/mL TNF or 100 μg/mL 
poly(I:C) for the indicated time and protein extracts were subjected to immunoblotting (N = 1). 
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Fig. S10. Analysis of caspase-8 and caspase-3 cleavage in poly(I:C)-stimulated fibroblasts 
Fibroblasts were stimulated with 20 μg/mL poly(I:C) for 24 hours and protein extracts were 
subjected to immunoblotting (N = 1). THP-1 cells stimulated with 50 μM of etoposide for 6 
hours were used as a positive control of caspase cleavage.  
Control P2
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Full length caspase-3
Full length caspase-8
Cleaved 
caspase-3
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Fig. S11. Cytokine production in whole blood after PHA stimulation 
Cytokine amounts were measured 24 hours after stimulation in whole blood of healthy controls 
(grey circles) and patients (colored circles: P1 – magenta, P3 – blue, P4 – green, P2 before 
HSCT – red; P2 after HSCT – red star). Stimulations were done using 10 μg/mL PHA. Data 
were normalized on lymphocyte counts to correct for lymphopenia. P-values were calculated 
using two-tailed Mann-Whitney test, excluding the data of P2 after HSCT. 
 
  
NS NS NS
P < 0.0001 P = 0.0007
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Fig. S12. Cytokine production in whole blood after Pam2CSK4 or Pam3CSK4 
stimulation  
Cytokine amounts were measured 24 hours after stimulation in whole blood of healthy controls 
(grey circles) and patients (colored circles: P1 – magenta, P3 – blue, P4 – green, P2 before 
HSCT – red; P2 after HSCT – red star). Stimulations were done using Pam2CSK4 (1 g/mL) 
or Pam2CSK4 (1 g/mL) plus IFN- (2 x 104 IU/mL), Pam3CSK4 (1 g/mL) or Pam3CSK4 
(1 g/mL) plus IFN- (2 x 104 IU/mL). Data were normalized on lymphocyte counts to correct 
for lymphopenia. P-values were calculated using two-tailed Mann-Whitney test, excluding the 
data of P2 after HSCT. 
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Fig. S13. IL-1β in whole blood after LPS stimulation 
IL-1β was measured in whole blood after 24 hour stimulation using 1 μg/mL LPS or 1 μg/mL 
LPS plus 20,000 IU/mL IFN-. To account for lymphopenia data were corrected for 
lymphocyte counts. Controls are shown as grey circles, patients as colored circles (P1 – 
magenta, P3 – blue, P4 – green, P2 before HSCT – red; P2 after HSCT – red star).  P-values 
were calculated using two-tailed Mann-Whitney test, excluding the data of P2 after HSCT. 
  
NS
P = 0.0043
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Fig. S14. RIPK1-deficient THP-1 cells have normal phosphorylation of MAPK p42/44 
(ERK2/1) and p65 subunit of NF-B  
Wild-type THP-1 and THP-1
RIPK1-/-
 cells (one clone each) were treated with 50 ng/mL PMA 
for 3 days, stimulated with 1 μg/mL LPS for the indicated time and the extracted proteins were 
analyzed by immunoblotting (N = 2).  
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Fig. S15. No caspase-8 and caspase-3 cleavage in LPS-stimulated THP-1 cells 
Wild-type THP-1 and THP-1
RIPK1-/-
 cells (one clone each) were stimulated with 5 μg/mL LPS 
for 48 hours and the extracted proteins were analyzed by immunoblotting (N = 2). THP-1 cells 
stimulated with 50 μM of etoposide for 6 hours were used as a positive control of caspase 
cleavage. 
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Fig. S16. IL-1 release during pyroptosis of wild-type THP-1 cells and necroptosis of 
THP-1
RIPK1-/-
 cells 
Wild-type THP-1 cells were stimulated with 5 μg/mL LPS for 48 hours and 20 μM Nigericin 
for the last 90 minutes in the presence of the indicated compounds. THP-1
RIPK1-/-
 cells were 
stimulated with 5 μg/mL LPS for 48 hours in the presence of the indicated compounds. IL-1 
was analysed in supernatants by immunoblotting (N = 1). 
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Fig. S17. Inhibitors of necroptosis do not rescue reduced IL-6 production in  
THP-1
RIPK1-/-
 cells 
Wild-type THP-1 (2 clones) and THP-1
RIPK1-/-
 cells (4 clones) were stimulated with 5 μg/mL 
LPS for 24 hours in the presence of the indicated compounds. IL-6 was measured in 
supernatants by ELISA. P-values were calculated using two-tailed unpaired T-test; graphs 
show mean values ± SEM. 
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Fig. S18. Cell death in gastrointestinal biopsies from P1, P2 and controls 
(A) An occasional epithelial cell with apoptotic morphology in colonic crypt epithelium of 
patient P1. Hematoxylin and eosin staining. Scale bar = 50 μm. 
(B) An occasional epithelial cell with apoptotic morphology in duodenal crypt epithelium of 
patient P2. Hematoxylin and eosin staining. Scale bar = 50 μm. 
(C) An occasional epithelial cell with apoptotic morphology in crypt epithelium of a colonic 
biopsy from a child with idiopathic inflammatory bowel disease. Hematoxylin and eosin 
staining. Scale bar = 50 μm. 
(D) Immunostaining for cleaved caspase-3 showing occasional positive cells, including cells 
with apoptotic morphology, in the surface epithelium, lamina propria and crypt epithelium of 
the colon of patient P1. Scale bar = 50 μm. 
(E) Immunostaining for cleaved caspase-3 showing an occasional positive cell in duodenal 
crypt epithelium of patient P2. Scale bar = 50 μm. 
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(F) Immunostaining for cleaved caspase-3 showing occasional positive cells in crypt 
epithelium of a colonic biopsy from a child with idiopathic inflammatory bowel disease. Scale 
bar = 50 μm. 
(G) Immunostaining for cleaved caspase-3 showing occasional positive cells in the surface 
epithelium, lamina propria and crypt epithelium of a histologically normal colonic biopsy. 
Scale bar = 50 μm. 
(H) Immunostaining for cleaved caspase-3 showing an occasional positive cell in crypt 
epithelium of a histologically normal duodenal biopsy. Scale bar = 50 μm. 
(I) Immunostaining for CD3 showing negativity of an apoptotic colonic crypt epithelial cell of 
patient P1. Scale bar = 50 μm. 
(J) Immunostaining for cytokeratin showing positive staining of apoptotic cells and apoptotic 
bodies in the superficial colonic lamina propria of patient P1. Together with (I) this indicates 
epithelial origin of the apoptotic cells. Scale bar = 50 μm. 
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